Comprehensive Hematology Oncology, Llc

CLIA Laboratory Citation Details

2
Total Citations
6
Total Deficiencyies
6
Unique D-Tags
CMS Certification Number 10D2145450
Address 425 South Parson Avenue Suite 101, Brandon, FL, 33511
City Brandon
State FL
Zip Code33511
Phone813 278-5062
Lab DirectorSYED ABID

Citation History (2 surveys)

Survey - November 23, 2021

Survey Type: Special

Survey Event ID: 10DM11

Deficiency Tags: D3000 D0000

Summary:

Summary Statement of Deficiencies D0000 A special focused COVID-19 reporting survey was conducted on 11/23/21 at Comprehensive Hematology Oncology LLC, a clinical laboratory in Brandon, FL. Comprehensive Hematology Oncology LLC was not in compliance with Code of Federal Regulations (CFR), Part 493, requirements of clinical laboratories. The following Condition was cited: D3000-Facility Administration 493.1100 D3000 FACILITY ADMINISTRATION CFR(s): 493.1100 Each laboratory that performs nonwaived testing must meet the applicable requirements under 493.1101 through 493.1105, unless HHS approves a procedure that provides equivalent quality testing as specified in Appendix C of the State Operations Manual (CMS Pub. 7). (a) Reporting of SARS-CoV-2 test results During the Public Health Emergency, as defined in 400.200 of this chapter, each laboratory that performs a test that is intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19 (hereinafter referred to as a "SARS-CoV-2 test") must report SARS-CoV-2 test results to the Secretary in such form and manner, and at such timing and frequency, as the Secretary may prescribe. This CONDITION is not met as evidenced by: Based on record review and interview with the Office Manager, the laboratory failed to report SARS-CoV-2 antigen results to the Department of Health (DOH) from 08/18 /2021 through 11/17/2021 for a total of 59 Patient results. The findings included: Review of the Clinical Laboratory Improvement Amendments (CLIA) Application for Certification (Form CMS-116) signed by the Laboratory Director on 11/15/2021 revealed that the laboratory performed Abbott Binox Now COVID-19 Antigen testing. On 11/23/2021 at 11:20 AM, per phone call, the Office Manager stated that they did not report the COVID-19 Antigen results to the DOH. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - September 12, 2019

Survey Type: Special

Survey Event ID: GKWJ11

Deficiency Tags: D2016 D6000 D2130 D6016

Summary:

Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of the laboratory's proficiency testing records for 2019, the laboratory did not have successful performance in proficiency testing for the specialty of hematology. Refer to D2130. Findings include: Review of the American Proficiency Institute (API) proficiency testing records and the review of the Centers for Medicare & Medicaid Services (CMS) 153 and 155 reports, on September 12, 2019 on or about 10:00 AM, showed that the laboratory had unsatisfactory testing scores for the analyte, complete blood count (CBC) which is made up of the following Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- tests: white blood cell count (WBC), red blood cell count (RBC), hematocrit (HCT), hemoglobin (HGB), platelets (PLT), and white blood cell differential (WBC Diff) for two out of three testing events in 2019. D2130 HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on the review of the Centers for Medicare & Medicaid Services (CMS) 153 and 155 reports and the laboratory's proficiency testing records, the laboratory did not have successful performance in proficiency testing in the specialty of hematology. Findings include: On September 12, 2019 on or about 10:00 AM the American Proficiency Institute (API) proficiency testing records and the CMS 153 and 155 reports were reviewed. The review showed that the laboratory failed to achieve satisfactory performance for the following tests: white blood cell count (WBC), red blood cell count (RBC), hematocrit (HCT), hemoglobin (HGB), platelets (PLT), and white blood cell differential (WBC Diff) as shown below. Event #1, 2019 WBC-0% RBC-0% HGB-0% HCT-0% PLT-0% WBC Diff-0% Event #2, 2019 WBC-0% RBC- 0% HGB-0% HCT-0% PLT-0% WBC Diff-0% D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on the review of the laboratory's proficiency testing records, the laboratory director failed to ensure that the laboratory maintained a satisfactory score for proficiency testing in the specialty of hematology. Findings include: On September 12, 2019, on or about 10:00 AM, the American Proficiency Institute (API) proficiency records and the Centers for Medicare & Medicaid Service (CMS) 153 and 155 reports were reviewed. The review showed that the laboratory had unsatisfactory testing scores for two out of three testing events for the following analytes; white blood cell count (WBC), red blood cell count (RBC), hematocrit (HCT), hemoglobin (HGB), platelets (PLT), and white blood cell differential (WBC Diff), in the specialty of hematology. The laboratory director is responsible for ensuring that the laboratory maintains successful participation in proficiency testing. Refer to D2130. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as -- 2 of 3 -- required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on the review of the laboratory's proficiency testing scores, the laboratory director failed to ensure that the laboratory performed proficiency testing in such a manner as to achieve and maintain successful participation in proficiency testing for the following analytes; white blood cell count (WBC), red blood cell count (RBC), hematocrit (HCT), hemoglobin (HGB), platelets (PLT), and white blood cell differential (WBC Diff) in the specialty of hematology. Findings Include: The review of the American Proficiency Institute (API) proficiency testing records and the Centers for Medicare & Medicaid Services (CMS) 153 and 155 reports on September 12, 2019 on or about 10:00 AM showed that the laboratory received unsatisfactory proficiency testing scores as shown below. Event #1, 2019 WBC-0% RBC-0% HGB- 0% HCT-0% PLT-0% WBC Diff-0% Event #2, 2019 WBC-0% RBC-0% HGB-0% HCT-0% PLT-0% WBC Diff-0% -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access